-

ODONATE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Odonate Therapeutics, Inc. - ODT

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Odonate Therapeutics, Inc. (NasdaqGS: ODT).

On August 24, 2020, the Company disclosed disappointing results from the trial of its sole drug candidate, tesetaxel. On March 22, 2021, the Company disclosed that it was ending development of tesetaxel following feedback from the U.S. Food and Drug Administration that the drug was unlikely to receive approval on the basis of its clinical data package, and that it would be winding down operations.

The Company has been sued in a securities class action lawsuit for failing to disclose material information, violating federal securities laws. Recently, the court in that case denied the Company’s motion to dismiss, allowing the case to move forward

KSF’s investigation is focusing on whether Odonate’s officers and/or directors breached their fiduciary duties to Odonate’s shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Odonate shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-odt/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

Industry:

Kahn Swick & Foti, LLC

NASDAQ:ODT
Release Versions
English

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

More News From Kahn Swick & Foti, LLC

KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV) to Chiesi Group. Under the terms of the proposed transaction, shareholders of KalVista will receive $27.00 in cash for each share of KalVista that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequ...

Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Assertio Holdings, Inc. (NasdaqCM: ASRT) to Garda Therapeutics. Under the terms of the proposed transaction, shareholders of Assertio will receive $18.00 per share in cash and a contingent value right. KSF is seeking to determine whether this consideration and the process that led to it are adequate,...

UniFirst Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of UniFirst Corporation - UNF

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of UniFirst Corporation (NYSE: UNF) to Cintas Corporation (NasdaqGS: CTAS). Under the terms of the proposed transaction, shareholders of UniFirst will receive $155.00 in cash and 0.7720 shares of Cintas stock for each share of UniFirst that they own. KSF is seeking to determine whether this considerati...
Back to Newsroom